Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs

Retrieved on: 2019-04-21 01:03:45

Tags for this article:

Biotechnology

Drug discovery

Click the tags to see associated articles and topics

Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs. View article details on hiswai:

Excerpt

<div>Michael Gilman, a partner in <b>Atlas Venture</b>, will become full-time CEO of the company, which is named for the fictional planet of Arrakis in Frank ...</div>

Article found on:

View Original Article